The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease-Reference-Cited by-同舟云学术

The successful use of subcutaneous abatacept in refractory anti- human transcriptional intermediary factor 1-gamma dermatomyositis skin and oesphagopharyngeal disease

Published:2018-05-22 Issue: Volume: Page:
ISSN:1462-0324
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Rodziewicz Mia¹,Kiely Patrick¹

Affiliation:

1. Department of Rheumatology, St George’s University Hospitals NHS Foundation Trust, London, UK

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/advance-article-pdf/doi/10.1093/rheumatology/key146/24844121/key146.pdf

Reference8 articles.

1. Factors associated with clinical remission of skin disease in dermatomyositis;Wolstencroft;JAMA Dermatol,2018

2. Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change;Anyanwu;Br J Dermatol,2015

3. Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells;Nagaraju;Clin Immunol,1999

4. Abatacept reduces levels of switched memory B cells, autoantibodies, and immunoglobulins in patients with rheumatoid arthritis;Scarsi;J Rheumatol,2014

5. Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial;Sokolove;Ann Rheum Dis,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical features of dermatomyositis patients with anti-TIF1 antibodies: A case based comprehensive review;Autoimmunity Reviews;2023-12

2. A comprehensive review of dermatomyositis treatments - from rediscovered classics to promising horizons;Expert Review of Clinical Immunology;2023-10-17

3. Therapeutic Effects of Treating COVID-19 Vaccine-Induced Anti-TIF1-γ-Positive Dermatomyositis;Medicina;2023-09-20

4. The role of bDMARDs in idiopathic inflammatory myopathies: A systematic literature review;Autoimmunity Reviews;2023-02

5. Past, Present, and Future in Dermatomyositis Therapeutics;Current Treatment Options in Rheumatology;2022-07-26